INTRODUCTION Alzheimer's disease (AD) is the predominant dementia globally, with
heterogeneous presentation and penetrance of clinical symptoms, variable presence of …

Alzheimer's disease (AD) is the most common type of dementia, affecting millions of people
worldwide; however, no disease-modifying treatments are currently available. Genome-wide …

Alzheimer's dementia commonly impacts the health of older adults and lacks any
preventative therapy. While Alzheimer's dementia risk has a substantial genetic component …

Over 25 genes are known to affect the risk of developing Alzheimer disease (AD), the most
common neurodegenerative dementia. However, mechanistic insights and improved …

Background Genome-wide association studies (GWAS) have identified over 56 susceptibility
loci associated with Alzheimer's disease (AD), but the genes responsible for these …

Background: Our understanding of the pathophysiology underlying Alzheimer's disease
(AD) has benefited from genomic analyses, including those that leverage polygenic risk …

Abstract Introduction Patients with predementia Alzheimer's disease (AD) and at‐risk
subjects are targets for promising disease‐modifying treatments, and improved polygenic …

Genome-wide association studies (GWAS) have identified numerous susceptibility loci for
Alzheimer's disease (AD). However, utilizing GWAS to identify high-confidence AD risk …

Alzheimer's disease (AD) is a genetically complex, multifactorial neurodegenerative
disease. It affects more than 45 million people worldwide and currently remains untreatable …

Introduction Alzheimer's disease (AD) is heterogeneous, both clinically and
neuropathologically. We investigated whether polygenic risk scores (PRSs) integrated with …